Backgrounds/Aims Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant is closely associated with the occurrence and development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the role and mechanism of TM6SF2 E167K variant during MASLD progression are not yet fully understood.
Methods The Tm6sf2167K knock-in (KI) mice were subjected to high-fat diet (HFD). Hepatic lipid levels of Tm6sf2167K KI mice were detected by lipidomics analysis. Thin-layer chromatography (TLC) was used to measure the newly synthesized triglyceride (TG) and phosphatidylcholine (PC).
Results The TM6SF2 E167K variant significantly aggravated hepatic steatosis and injury in HFD-induced mice. Decreased polyunsaturated PC level and increased polyunsaturated TG level were found in liver tissue of HFD-induced Tm6sf2167K KI mice. Mechanistic studies demonstrated that the TM6SF2 E167K variant increased the interaction between TM6SF2 and PNPLA3, and impaired PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to PC. The TM6SF2 E167K variant increased the level of fatty acid-induced malondialdehyde and reactive oxygen species, and decreased fatty acid-downregulated cell membrane fluidity. Additionally, the TM6SF2 E167K variant decreased the level of hepatic PC containing C18:3, and dietary supplementation of PC containing C18:3 significantly attenuated the TM6SF2 E167K-induced hepatic steatosis and injury in HFD-fed mice.
Conclusions The TM6SF2 E167K variant could promote its interaction with PNPLA3 and inhibit PNPLA3-mediated transfer of PUFAs from TG to PC, resulting in the hepatic steatosis and injury during MASLD progression. PC containing C18:3 could act as a potential therapeutic supplement for MASLD patients carrying the TM6SF2 E167K variant.
Citations
Citations to this article as recorded by
Association of Circadian Rhythms With the Risk of Chronic Liver Disease: Findings From a Large Prospective Study Rong Yang, Can Shen, Yu Jia, Yi Yao, Yiheng Zhou, Yu Cheng, Yonglang Cheng, Rui Zeng, Zhi Wan, Qian Zhao, Dongze Li, Xiaoyang Liao Clinical and Translational Gastroenterology.2026; 17(1): e00949. CrossRef
High-protein diets and metabolic dysfunction-associated steatotic liver disease: A double-edged sword in liver health Hong-Yuan Yin, Qian-Hui You, Wei-Jie Zhang, Guang Ji, Yan-Qi Dang World Journal of Gastroenterology.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models Jack Leslie, Kishore A. Krishnamurthy, Indresh K. Gopalsamy, Patricia Inacio, Meritxell Huch, Suchira Gallage, Fiona Oakley, Michele Vacca Nature Reviews Gastroenterology & Hepatology.2026; 23(4): 286. CrossRef
1-O-acetylbritannilactone alleviates high-fat diet-induced fatty liver by covalently targeting NLRP3 Tianyang Jin, Yanni Zhao, Tingxin Xu, Yi Fang, Yaqian Cui, Wenqi Liu, Yongqiang Xiong, Jiaxi Ye, Wu Luo, Bo Hong, Guang Liang, Xiang Hu, Lijiang Huang, Yi Wang International Immunopharmacology.2026; 174: 116351. CrossRef
Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis Gang Zhou, Xihan Gu, Xinyao Zhou, Shuai Chen, Hanyang Liu, Jing Wang BMJ Open Gastroenterology.2026; 13(1): e002123. CrossRef
Lipid metabolism-MAFLD crosstalk: mechanisms and therapy Bojia Li, Shengai Piao, Yin Fu, Qiang Fu, Peiyao Qin, Weitai Kong, Yidi Ma, Zhe Zhang, Xue Fang, Xiaoyang Hu Frontiers in Endocrinology.2026;[Epub] CrossRef
Current status survey and risk factor analysis of metabolic dysfunction-associated steatotic liver disease among adolescents in Hainan Province Shuo Zhou, Daya Zhang, Runyu Chen, Yan-ting Lv, Da Li, Xianfeng Huang, Fengjiao Mao, Shimei Huang, Shiju Chen, Chen Chen, Ying Mo, Yiping Du, Yuliang Huang, Fan Zeng, Qicen Yao, Feihu Bai Scientific Reports.2026;[Epub] CrossRef
Selenium Protects Against Cadmium-Induced Hepatotoxicity via Regulation of Lipid Metabolism and Inflammatory Pathways Zilong Wu, Xinyi Chen, Xiaoying Pan, Kai Luo, Zixiong Zhang, Changyu Zhou, Haibo Wang, Chuying Huang Frontiers in Bioscience-Landmark.2026;[Epub] CrossRef
Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review Aleksandra Klisic, Ratko Tomašević, Slavko Djuraskovic, Filiz Mercantepe, Ana Ninic Archives of Medical Science.2026;[Epub] CrossRef
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603. CrossRef
Microbial metabolites contribute to the pathogenesis of metabolic dysfunction-associated fatty liver disease in high-fat diet-fed mice Kai-Wen Cai, Zhen-Chuan Lin, Xue-Mei Zhang, Jia-Yun Yu, Tian-jiao Cui, Yi-Qing Zhang, Rong-Hua Zou, Zhi-Hua Zheng, Yao-Liang Zhou, Ting Zhu, Yong-Ping Lu Microbial Pathogenesis.2026; 218: 108634. CrossRef
Genetics and epigenetics in tumor necrosis factor-alpha (TNF-α) and transmembrane 6 superfamily member 2 (TM6SF2) in alcohol induced liver cirrhosis Bhagyalakshmi Shankarappa, Jayant Mahadevan, Pratima Murthy, Biju Viswanath, Harshad Devarbhavi, Sanjeev Jain, Meera Purushottam Frontiers in Medicine.2026;[Epub] CrossRef
Abnormal lipid metabolism in metabolic dysfunction-associated steatohepatitis (MASH) Wonseok Lee, You-Jin Choi, Hyuneui Park, Suwan Chae, Byung-Hoon Lee Toxicological Research.2026;[Epub] CrossRef
Dual effects of a high-protein diet on metabolic dysfunction-associated steatotic liver disease: Basic research on precision clinical interventions Ya-Rong Ma, Wen-Long Miao, Na Li, Gui-Zhen Zhang, Zhi-Gang Ren World Journal of Gastroenterology.2026;[Epub] CrossRef
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD” Baokai Sun, Likun Zhuang Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef
TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD” Andrea Caddeo, Rosellina M. Mancina Clinical and Molecular Hepatology.2025; 31(1): 293. CrossRef
Causal roles of immune cells and metabolites in chronic pancreatitis: a mendelian randomization study Chao Zhang, Tao Yang, Yuan Yu, Qian Jia, Wan-Meng Xiao, Sha Liu, Ze-Hui Yu, Cheng-Li Wen, Yan Wei, Hao Li, Mu-Han Lü Hereditas.2025;[Epub] CrossRef
Effects of polyphenols on non-alcoholic fatty liver disease: a case study of resveratrol Ying Zhao, Jiali Ren, Weisan Chen, Xinchen Gao, Hongjian Yu, Xiankuan Li, Yanchao Zheng, Jinlong Yang Food & Function.2025; 16(8): 2926. CrossRef
Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease Mohammad Shafi Kuchay, Narendra Singh Choudhary, Bruno Ramos-Molina American Journal of Physiology-Cell Physiology.2025; 328(5): C1637. CrossRef
Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement Indrajit Bhattacharya, Deep Kumar Maity, Amit Kumar, Sampriti Sarkar, Teeshyo Bhattacharya, Amrita Sahu, Remya Sreedhar, Somasundaram Arumugam Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(10): 13647. CrossRef
Liver disease trends in the Asia-Pacific region for the next 50 years Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim Clinical and Molecular Hepatology.2025; 31(3): 671. CrossRef
Wen-Yue Liu, Xiaofang Zhang, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Rafael S. Rios, Kenneth I. Zheng, Hong-Lei Ma, Xiao-Dong Wang, Qiuwei Pan, Robert J. de Knegt, Luca Valenti, Mohsen Ghanbari, Ming-Hua Zheng
Clin Mol Hepatol 2022;28(2):183-195. Published online November 28, 2021
Background/Aims Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic dysfunction. Among the multiple factors, genetic variation acts as important modifiers. Klotho, an enzyme encoded by the klotho (KL) gene in human, has been implicated in the pathogenesis of metabolic dysfunctions. However, the impact of variants in KL on NAFLD risk remains poorly understood. The aim of this study was to investigate the impact of KL rs495392 C>A polymorphism on the histological severity of NAFLD.
Methods We evaluated the impact of the KL rs495392 polymorphism on liver histology in 531 Chinese with NAFLD and replicated that in the population-based Rotterdam Study cohort. The interactions between the rs495392, vitamin D, and patatin-like phospholipase domain containing 3 (PNPLA3) rs738409 polymorphism were also analyzed.
Results Carriage of the rs495392 A allele had a protective effect on steatosis severity (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.42–0.89; P=0.010) in Chinese patients. After adjustment for potential confounders, the A allele remained significant with a protective effect (OR, 0.66; 95% CI, 0.45–0.98; P=0.040). The effect on hepatic steatosis was confirmed in the Rotterdam Study cohort. Additional analysis showed the association between serum vitamin D levels and NAFLD specifically in rs495392 A allele carriers, but not in non-carriers. Moreover, we found that the rs495392 A allele attenuated the detrimental impact of PNPLA3 rs738409 G allele on the risk of severe hepatic steatosis.
Conclusions The KL rs495392 polymorphism has a protective effect against hepatic steatosis in patients with NAFLD.
Citations
Citations to this article as recorded by
Unraveling chemotherapy-evoked hepatic dysfunction: a deep dive into cyclophosphamide-related liver injury Ehab E. Sharata, Mina Ezzat Attya, Marwa M. Khalaf, Remon Roshdy Rofaeil, Ramadan A. M. Hemeida, Amira M. Abo-Youssef Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(2): 2097. CrossRef
Buspirone combats cyclophosphamide-provoked hepatotoxicity in rats via activation of AMPK/Nrf2/HO-1 and suppression of NF-κB p65 /NLRP3 inflammasome pathways Marwa M. Khalaf, Ehab E. Sharata, Waleed A. I. Khallaf, Mina Ezzat Attya, Amira M. Abo-Youssef, Ramadan A. M. Hemeida, Remon Roshdy Rofaeil Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(4): 5483. CrossRef
Genetic modulators of metabolic dysfunction-associated steatotic liver disease (MASLD) and their epistatic interactions: from in vitro and animal models to clinical outcomes Fernanda G. Arriaga-González, Felipe de Jesús Castañeda-Córdova, Mauricio Díaz-Muñoz, Matthew Hoare, David J. Adams, Carla Daniela Robles-Espinoza, Christian Molina-Aguilar BMC Medical Genomics.2026;[Epub] CrossRef
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in the Indian Ethnicity: An Update Ravikanth Vishnubhotla, Govardhan Bale, Anand V. Kulkarni, Nageshwar Reddy Duvvur, Nagaraja Rao Padaki Journal of Clinical and Experimental Hepatology.2026; 16(6): 103616. CrossRef
Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology Javier Crespo, Marta Alonso-Peña, Carolina Jiménez-González, Lorena Cayón-Gonzalez, Paula Iruzubieta Pharmaceuticals.2026; 19(8): 1145. CrossRef
Nuclear mitochondrial interaction test reveals sex-dependent mitochondrial SNP-Klotho interactions on diabetes risk Tae Jung Oh, Hiroshi Kumagai, Kelvin Yen, Eileen M Crimmins, Thalida E Arpawong, Pinchas Cohen Journal of the Endocrine Society.2026;[Epub] CrossRef
Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation Sin Man Lam, Zehua Wang, Jin-Wen Song, Yue Shi, Wen-Yue Liu, Lin-Yu Wan, Kaibo Duan, Gek Huey Chua, Yingjuan Zhou, Guibin Wang, Xiahe Huang, Yingchun Wang, Fu-Sheng Wang, Ming-Hua Zheng, Guanghou Shui Cell Metabolism.2025; 37(1): 69. CrossRef
Levomilnacipran alleviates cyclophosphamide-induced hepatic dysfunction in male Wistar albino rats; emerging role of α-Klotho/TLR4/p38-MAPK/NF-κB p65 and caspase-3-driven apoptosis trajectories Ehab E. Sharata, Mina Ezzat Attya, Marwa M. Khalaf, Remon Roshdy Rofaeil, Amira M. Abo-Youssef, Ramadan A.M. Hemeida International Immunopharmacology.2025; 152: 114384. CrossRef
Apremilast attenuates methotrexate-induced hepatic injury in rats; insights into TLR4/NF-κB/P38 MAPK/caspase-3 and α-klotho/Nrf2/HO-1 signaling network interplay Reham H. Mohyeldin, Ehab E. Sharata, Mahmoud Abdelnaser, Ayman M. Ibrahim, Mina Ezzat Attya, Al Shaimaa Mahmoud Kotb, Ahmed S.Aboalela, Remon Roshdy Rofaeil Toxicology and Applied Pharmacology.2025; 505: 117596. CrossRef
The relationship of serum klotho levels and triglyceride glucose index-related indicators Yaoyao Zhou, Yaqi Wang, Fangli Li, Yiming Shi, Taotao Wu, Yingshuai Li Lipids in Health and Disease.2024;[Epub] CrossRef
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk Jacob Nysather, Eda Kaya, Paul Manka, Prakash Gudsoorkar, Wing-Kin Syn Advances in Kidney Disease and Health.2023; 30(4): 315. CrossRef
Emerging role of α-Klotho in energy metabolism and cardiometabolic diseases Yuanbin Liu, Mingkai Chen Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(10): 102854. CrossRef
Advances in genetic variation in metabolism-related fatty liver disease Fan Shi, Mei Zhao, Shudan Zheng, Lihong Zheng, Haiqiang Wang Frontiers in Genetics.2023;[Epub] CrossRef
Klotho Levels and Their Relationship with Inflammation and Survival among Alcoholic Patients Candelaria Martín-González, Elisa Espelosín-Ortega, Pedro Abreu-González, Camino Fernández-Rodríguez, Víctor Eugenio Vera-Delgado, Lourdes González-Navarrete, Alen García-Rodríguez, Antonio Martínez Riera, Emilio González-Reimers Biomolecules.2022; 12(8): 1151. CrossRef
CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice Rongrong Tan, Jiayang Li, Lu Liu, Qian Wu, Lei Fan, Ningning Ma, Chuwei Yu, Henglei Lu, Xuemei Zhang, Jing Chen, Likun Gong, Jin Ren International Journal of Molecular Sciences.2022; 23(24): 15931. CrossRef
First
Prev
